Current drug delivery最新文献_第2页

Gold Nanoparticle-Based Drug Delivery System for the Diagnosis and Treatment of Bacterial Meningitis 用于诊断和治疗细菌性脑膜炎的基于金纳米粒子的给药系统

IF 2.4 4区医学

Current drug delivery Pub Date : 2024-04-17 DOI: 10.2174/0115672018278607240405060054

Darsh Gautam, Vinay Pandit, Sanjay Kumar, Poonam Talwan, Tarun Sharma

{"title":"Gold Nanoparticle-Based Drug Delivery System for the Diagnosis and Treatment of Bacterial Meningitis","authors":"Darsh Gautam, Vinay Pandit, Sanjay Kumar, Poonam Talwan, Tarun Sharma","doi":"10.2174/0115672018278607240405060054","DOIUrl":"https://doi.org/10.2174/0115672018278607240405060054","url":null,"abstract":": Managing bacterial pathogens in the central nervous system is an immense issue for researchers all around the globe. The problem of these infections remains throughout the population, regardless of the discovery of several possible medicines. The major obstacle to drug delivery is the BBB, but only a few medicines that fulfill demanding requirements can penetrate it. Considering inadequate antibiotic alternatives and the increasing development of resistance, it is more important than ever to find new approaches to address this worldwide problem. Medical nanotechnology has evolved as a cutting-edge and effective means of treating many of the most difficult CNS illnesses, including bacterial meningitis. Various metallic nanoparticles, such as gold, silver, and titanium oxide, have shown bactericidal potential. Gold nanoparticles have gotten a great deal of interest due to their excellent biocompatibility, simplicity of surface modification, and optical qualities. The current study described AuNP-based detection and therapy options against meningitis-- causing bacteria, including bacterial pathogens' mechanisms for crossing BBB and AuNPs' mode of Action against those bacteria. The current study looked into green synthesized bactericidal gold nanoparticles-based therapy techniques for diagnosing and intervening in bacterial meningitis. Nevertheless, more research is needed before these laboratory findings can be translated into therapeutic trials. Nonetheless, we can confidently assert that the knowledge acquired and addressed in this study will benefit neuro-nanotechnology researchers.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":"17 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140612387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Epic Advancement in Targeting Macrophages for Cancer Therapy Approach 针对巨噬细胞的癌症治疗方法取得重大进展

IF 2.4 4区医学

Current drug delivery Pub Date : 2024-04-09 DOI: 10.2174/0115672018299798240403062508

Lu Xiaohong, Fu Qiuxia, Li Ruie, Wang Daijie, Tobias Achu Muluh, Yan Zhang

{"title":"An Epic Advancement in Targeting Macrophages for Cancer Therapy Approach","authors":"Lu Xiaohong, Fu Qiuxia, Li Ruie, Wang Daijie, Tobias Achu Muluh, Yan Zhang","doi":"10.2174/0115672018299798240403062508","DOIUrl":"https://doi.org/10.2174/0115672018299798240403062508","url":null,"abstract":": Macrophages are immune cells with high heterogeneity and plasticity, crucial for recognizing and eliminating foreign substances, including cancer cells. However, cancer cells can evade the immune system by producing signals that cause macrophages to switch to a pro-tumor phenotype, promoting tumor growth and progression. Tumor-associated macrophages, which infiltrate into tumor tissue, are important immune cells in the tumor microenvironment and can regulate cancer's growth, invasion, and metastasis by inhibiting tumor immunity. This review article highlights the characteristics of tumor-associated macrophages and their role in the occurrence and development of cancer. It outlines how reprogramming macrophages towards an anti-tumor phenotype can improve the response to cancer therapy. Explore the intricate process of engineered nanoparticles serving as carriers for immunostimulatory molecules, activating macrophages to instigate an anti-tumor response. Finally, it summarizes several studies demonstrating targeting macrophages is a potential in preclinical cancer models. Several challenges must be addressed in developing effective macrophage-targeted therapies, such as the heterogeneity of macrophage subtypes and their plasticity. Further research is needed to understand the mechanisms underlying macrophage function in the tumor microenvironment and identify novel targets for macrophage-directed therapies. Targeting macrophages is a promising and innovative approach to improving cancer therapy and patient outcomes.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":"249 1","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140560081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Doxorubicin-loaded Echogenic Macroemulsion for Targeted Drug Delivery. 用于靶向给药的负载型多柔比星回声大乳剂的评估

IF 2.4 4区医学

Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230403111118

Jong-Ryul Park, Gayoung Kim, Jongho Won, Chul-Woo Kim, Donghee Park

{"title":"Evaluation of Doxorubicin-loaded Echogenic Macroemulsion for Targeted Drug Delivery.","authors":"Jong-Ryul Park, Gayoung Kim, Jongho Won, Chul-Woo Kim, Donghee Park","doi":"10.2174/1567201820666230403111118","DOIUrl":"10.2174/1567201820666230403111118","url":null,"abstract":"Background: The latest technology trend in targeted drug delivery highlights stimuliresponsive particles that can release an anticancer drug in a solid tumor by responding to external stimuli.Objective: This study aims to design, fabricate, and evaluate an ultrasound-responsive drug delivery vehicle for an ultrasound-mediated drug delivery system.Methods: The drug-containing echogenic macroemulsion (eME) was fabricated by an emulsification method using the three phases (aqueous lipid solution as a shell, doxorubicin (DOX) contained oil, and perfluorohexane (PFH) as an ultrasound-responsive agent). The morphological structure of eMEs was investigated using fluorescence microscopy, and the size distribution was analyzed by using DLS. The echogenicity of eME was measured using a contrast-enhanced ultrasound device. The cytotoxicity was evaluated using a breast cancer cell (MDA-MB-231) via an in vitro cell experiment.Results: The obtained eME showed an ideal morphological structure that contained both DOX and PFH in a single particle and indicated a suitable size for enhancing ultrasound response and avoiding complications in the blood vessel. The echogenicity of eME was demonstrated via an in vitro experiment, with results showcasing the potential for targeted drug delivery. Compared to free DOX, enhanced cytotoxicity and improved drug delivery efficiency in a cancer cell were proven by using DOX-loaded eMEs and ultrasound.Conclusion: This study established a platform technology to fabricate the ultrasound-responsive vehicle. The designed drug-loaded eME could be a promising platform with ultrasound technology for targeted drug delivery.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"785-793"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9247889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanocarrier Mediated Intranasal Drug Delivery Systems for the Management of Parkinsonism: A Review. 纳米载体介导的鼻内给药系统用于治疗帕金森病：综述。

IF 2.4 4区医学

Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230523114259

Archita Kapoor, Abdul Hafeez, Poonam Kushwaha

{"title":"Nanocarrier Mediated Intranasal Drug Delivery Systems for the Management of Parkinsonism: A Review.","authors":"Archita Kapoor, Abdul Hafeez, Poonam Kushwaha","doi":"10.2174/1567201820666230523114259","DOIUrl":"10.2174/1567201820666230523114259","url":null,"abstract":"The transport of drugs to the brain becomes a key concern when treating disorders of the central nervous system. Parkinsonism is one of the major concerns across the world populations, which causes difficulty in coordination and balance. However, the blood-brain barrier is a significant barrier to achieving optimal brain concentration through oral, transdermal, and intravenous routes of administration. The intranasal route with nanocarrier-based formulations has shown potential for managing Parkinsonism disorder (PD). Direct delivery to the brain through the intranasal route is possible via the olfactory and trigeminal pathways using drug-loaded nanotechnology-based drug delivery systems. The critical analysis of reported works demonstrates dose reduction, brain targeting, safety, effectiveness, and stability for drug-loaded nanocarriers. The important aspects of intranasal drug delivery, PD details, and nanocarrier-based intranasal formulations in PD management with a discussion of physicochemical characteristics, cell line studies, and animal studies are the major topics in this review. Patent reports and clinical investigations are summarized in the last sections.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"709-725"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9692815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Insight on Skin Cancer About Different Targets With Update on Clinical Trials and Investigational Drugs. 深入了解皮肤癌的不同靶点，以及临床试验和研究药物的最新情况。

IF 2.4 4区医学

Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230726150642

Suraj Vishwas, Swarnali Das Paul, Deepika Singh

{"title":"An Insight on Skin Cancer About Different Targets With Update on Clinical Trials and Investigational Drugs.","authors":"Suraj Vishwas, Swarnali Das Paul, Deepika Singh","doi":"10.2174/1567201820666230726150642","DOIUrl":"10.2174/1567201820666230726150642","url":null,"abstract":"Cancer is a diverse disease caused by transcriptional changes involving genetic and epigenetic features that influence a huge variety of genes and proteins. Skin cancer is a potentially fatal disease that affects equally men and women globally and is characterized by many molecular changes. Despite the availability of various improved approaches for detecting and treating skin cancer, it continues to be the leading cause of death throughout society. This review highlights a general overview of skin cancer, with an emphasis on epidemiology, types, risk factors, pathological and targeted facets, biomarkers and molecular markers, immunotherapy, and clinical updates of investigational drugs associated with skin cancer. The skin cancer challenges are acknowledged throughout this study, and the potential application of novel biomarkers of skin cancer formation, progression, metastasis, and prognosis is explored. Although the mechanism of skin carcinogenesis is currently poorly understood, multiple articles have shown that genetic and molecular changes are involved. Furthermore, several skin cancer risk factors are now recognized, allowing for efficient skin cancer prevention. There have been considerable improvements in the field of targeted treatment, and future research into additional targets will expand patients' therapeutic choices. In comparison to earlier articles on the same issue, this review focused on molecular and genetic factors and examined various skin cancer-related factors in depth.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"852-869"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9876282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparing Recovery from Desflurane and Sevoflurane in Patients with Different Body Fat Percentages: A Randomized Controlled Trial. 比较地氟醚和七氟醚在不同体脂百分比患者中的恢复:一项随机对照试验。

IF 2.8 4区医学

Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230328115354

Silu Cao, Huijuan Wang, Lijun Tang, Guanghui An

{"title":"Comparing Recovery from Desflurane and Sevoflurane in Patients with Different Body Fat Percentages: A Randomized Controlled Trial.","authors":"Silu Cao, Huijuan Wang, Lijun Tang, Guanghui An","doi":"10.2174/1567201820666230328115354","DOIUrl":"10.2174/1567201820666230328115354","url":null,"abstract":"Introduction: Increased body fat may influence the partition coefficients of inhaled anesthetics. We compared patient responses to desflurane and sevoflurane anesthesia, as measured by a quicker recovery and fewer complications, in patients with higher body fat percentages, not only obese people.Methods: This study included 120 patients. Participants were stratified into low or high body fat percentages groups using bioelectrical impedance analysis and were randomized 1:1 to receive desflurane or sevoflurane as an inhaled anesthetic, recorded as Low-Desflurane, Low-Sevoflurane, High- Desflurane, and High-Sevoflurane. Recovery time, Riker sedation-agitation scale scores, and complications were recorded over 1 hour in the post-anesthesia care unit.Results: A total of 106 patients were analyzed. There were no significant differences in the overall recovery time between the patient subgroups with higher and lower body fat percentages; in addition, there were no significant differences in the incidence of nausea, vomiting,dizziness, or headache (all p>0.05). However, the incidence of agitation emergence in the HighSevoflurane subgroup was significantly higher compared to the High-Desflurane subgroup (33.3% vs.7.41%; p = 0.043).Conclusion: In conclusion, for patients with a lower body fat percentage, both desflurane and sevoflurane can provide good and fast recovery; for patients with a higher body fat percentage,desflurane may provide better recovery with a lower incidence of agitation emergence compared to sevoflurane.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"623-630"},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9596356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Self Nanoelmusifying Drug Delivery System of Rosuvastatin: Bioavailability Evaluation and In vitro - In vivo Correlation. 瑞舒伐他汀：生物利用度评估及体内外相关性研究

IF 2.4 4区医学

Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666221220104244

Nghia Thi Phan, Yen Thi Hai Tran, Linh Tran Nguyen, Yen Kieu Hoang, Cuong Khac Bui, Hoa Dang Nguyen, Giang Thi Thu Vu

{"title":"Self Nanoelmusifying Drug Delivery System of Rosuvastatin: Bioavailability Evaluation and In vitro - In vivo Correlation.","authors":"Nghia Thi Phan, Yen Thi Hai Tran, Linh Tran Nguyen, Yen Kieu Hoang, Cuong Khac Bui, Hoa Dang Nguyen, Giang Thi Thu Vu","doi":"10.2174/1567201820666221220104244","DOIUrl":"10.2174/1567201820666221220104244","url":null,"abstract":"Background: Rosuvastatin, most commonly used in the form of calcium salt, belongs to the statin groups of synthetic antihyperlipidemic agents. Rosuvastatin possesses high permeability, however, its aqueous solubility is poor, causing a slow dissolution rate in water. Consequently, this dissolution rate has a decisive role in the release and absorption of rosuvastatin in the gastrointestinal tube.Objective: The aims of this study were to evaluate the absorption of the drug from the self-nano emulsifying drug delivery system of rosuvastatin (Ros SNEDDS) compared to rosuvastatin substance and to develop a level-A in vitro-in vivo correlation (IVIVC) for Ros SNEDDS.Methods: An in-house developed LC-MS/MS method was used to determine the concentrations of rosuvastatin in dog plasma. Six beagle dogs received an intravenous dose, Ros SNEDDS, rosuvastatin substance. In vitro dissolution of the Ros SNEDDS was carried out with different conditions. Correlation models were developed from the dissolution and absorption results of Ros SNEDDS.Results: The results showed a 1.7-fold enhanced oral bioavailability and 2.1-time increase of rosuvastatin Cmax in Ros SNEDDS form, compared to the rosuvastatin substance. A 900 ml dissolution medium of pH of 6.6 has demonstrated its suitability, the in vitro dissolution model was studied and supported by the Weibull equation with a weighting factor of 1/y2 as it presented the lowest values of AIC.Conclusion: Ros SNEDDS demonstrated higher bioavailability of rosuvastatin in comparison to rosuvastatin substance and established a level A IVIVC used in future bioequivalence trials.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"734-743"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10764183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Novel Phytotherapy Application: Preparation, Characterization, Antioxidant Activities and Determination of Anti-inflammatory Effects by In vivo HET-CAM Assay of Chitosan-based DDSs Containing Endemic Helichrysum pamphylicum P.H. Davis & Kupicha Methanolic Extract. 一种新的植物疗法应用：壳聚糖基 DDSs 的制备、表征、抗氧化活性以及通过体内 HET-CAM 分析确定其抗炎效果，其中含有当地特有的 Helichrysum pamphylicum P.H. Davis & Kupicha 代谢提取物。

IF 2.4 4区医学

Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230328122504

Nurlan Ismailovi, H Tuba Kıyan, A Alper Öztürk

{"title":"A Novel Phytotherapy Application: Preparation, Characterization, Antioxidant Activities and Determination of Anti-inflammatory Effects by In vivo HET-CAM Assay of Chitosan-based DDSs Containing Endemic Helichrysum pamphylicum P.H. Davis & Kupicha Methanolic Extract.","authors":"Nurlan Ismailovi, H Tuba Kıyan, A Alper Öztürk","doi":"10.2174/1567201820666230328122504","DOIUrl":"10.2174/1567201820666230328122504","url":null,"abstract":"Background: Numerous pharmaceutical applications for chitosan, a polysaccharide made from the shells of crustaceans by deacetylating chitin that occurs naturally, are currently being researched. Chitosan, a natural polymer, is successfully used to prepare many drug-carrier systems, such as gel, film, nanoparticle, and wound dressing.Objective: Preparing chitosan gels without external crosslinkers is less toxic and environmentally friendly.Methods: Chitosan-based gels containing Helichrysum pamphylicum P.H. Davis & Kupicha methanolic extract (HP) were produced successfully.Results: The F9-HP coded gel prepared with high molecular weight chitosan was chosen as the optimum formulation in terms of pH and rheological properties. The amount of HP was found to be 98.83% ± 0.19 in the F9-HP coded formulation. The HP release from the F9-HP coded formula was determined to be slower and 9 hours prolonged release compared to pure HP. It was determined that HP release from F9-HP coded formulation with the DDSolver program was by anomalous (non-fickian) diffusion mechanism. The F9-HP coded formulation significantly showed DPPH free radical scavenger, ABTS•+ cation decolorizing and metal chelating antioxidant activity while weakly reducing antioxidant potential. According to the HET-CAM scores, strong anti-inflammatory activity was obtained by the F9-HP coded gel at a dose of 20 μg.embryo-1 (p<0.05 compared with SDS).Conclusion: In conclusion, it can be said that chitosan-based gels containing HP, which can be used in both antioxidant and anti-inflammatory treatment, were successfully formulated and characterized.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"901-916"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9607425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Advances in Nanocarrier-based Approaches to Atopic Dermatitis and Emerging Trends in Drug Development and Design. 基于纳米载体的特应性皮炎治疗方法的最新进展以及药物开发和设计的新趋势。

IF 2.4 4区医学

Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230508121716

Amisha, Dilpreet Singh, Balak Das Kurmi, Amrinder Singh

{"title":"Recent Advances in Nanocarrier-based Approaches to Atopic Dermatitis and Emerging Trends in Drug Development and Design.","authors":"Amisha, Dilpreet Singh, Balak Das Kurmi, Amrinder Singh","doi":"10.2174/1567201820666230508121716","DOIUrl":"10.2174/1567201820666230508121716","url":null,"abstract":"Atopic dermatitis (AD), commonly known as Eczema, is a non-communicable skin condition that tends to become chronic. The deteriorating immunological abnormalities are marked by mild to severe erythema, severe itching, and recurrent eczematous lesions. Different pharmacological approaches are used to treat AD. The problem with commercial topical preparations lies in the limitation of skin atrophy, systemic side effects, and burning sensation that decreases patient compliance. The carrier-based system promises to eliminate these shortcomings; thus, a novel approach to treating AD is required. Liposomes, microemulsions, solid lipid nanoparticles (SLNs), nanoemulsions, etc., have been developed recently to address this ailment. Despite extensive research in the development method and various techniques, it has been challenging to demonstrate the commercial feasibility of these carrier- based systems, which illustrates a gap among the different research areas. Further, different soft wares and other tools have proliferated among biochemists as part of a cooperative approach to drug discovery. It is crucial in designing, developing, and analyzing processes in the pharmaceutical industry and is widely used to reduce costs, accelerate the development of biologically innovative active ingredients, and shorten the development time. This review sheds light on the compilation of extensive efforts to combat this disease, the product development processes, commercial products along with patents in this regard, numerous options for each step of computer-aided drug design, including in silico pharmacokinetics, pharmacodynamics, and toxicity screening or predictions that are important in finding the drug-like compounds.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"932-960"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9432294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhanced Brain Targeting Delivery of Salvianic Acid Using Borneol as a Promoter of Blood/Brain Transport and Regulator of P-gp. 利用 Borneol 作为血脑转运促进剂和 P-gp 调节剂，增强丹参酸的脑靶向输送。

IF 2.4 4区医学

Current drug delivery Pub Date : 2024-01-01 DOI: 10.2174/1567201820666230119120314

Ailing Hui, Zheng Zhang, Jinghe Wang, Li Yang, Shaohuan Deng, Wencheng Zhang, An Zhou, Zeyu Wu

{"title":"Enhanced Brain Targeting Delivery of Salvianic Acid Using Borneol as a Promoter of Blood/Brain Transport and Regulator of P-gp.","authors":"Ailing Hui, Zheng Zhang, Jinghe Wang, Li Yang, Shaohuan Deng, Wencheng Zhang, An Zhou, Zeyu Wu","doi":"10.2174/1567201820666230119120314","DOIUrl":"10.2174/1567201820666230119120314","url":null,"abstract":"Background: Borneol can enhance the blood-brain barrier (BBB) permeability of some drugs and suppress the efflux transport of P-glycoprotein (P-gp), which will contribute to the brain delivery of salvianic acid A (SAA).Objective: The study aimed to develop an approach to improve the brain targeting delivery of SAA with the aid of borneol.Materials and methods: \"Borneol\" was involved in SAA via esterified prodrug SAA borneol ester (SBE) and combined administration (SAA-borneol, SAA-B). Subsequently, the blood-brain transport of SAA through brain/blood distribution and P-gp regulation via expression and function assay were investigated in rats.Results: The SBE and SAA-B-treated group received a three-fold brain concentration and longer t1/2 and retention period of active SAA than that of SAA alone (20.18/13.82 min vs. 6.48 min; 18.30/17.42 min vs. 11.46 min). In addition, blood to brain transport of active SAA in SBE was altered in comparison to that of SAA-B, ultimately resulting in a better drug targeting index (9.93 vs. 3.63). Further studies revealed that SBE-induced downregulation of P-gp expression occurred at the later stage of administration (60 min, P < 0.01), but SBE always showed a more powerful drug transport activity across BBB represented by Kp value of rhodamine 123 than SAA-B (30, 60 min, P < 0.05).Conclusion: The comparative results indicate that SBE exhibits prominent efficiency on SAA's targeting delivery through improved blood/brain metabolic properties and sustained inhibitory effect of \"borneol\" on P-gp efflux. Therefore, prodrug modification can be applied as a more effective approach for brain delivery of SAA.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"726-733"},"PeriodicalIF":2.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10550998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0